全部

1·The cardiac output, pulmonary vascular resistance and PAWP were more sensitive to changes of pulmonary function.

对肺功能变化较敏感的血流动力学指标是心输出量、肺血管阻力、肺小动脉嵌顿压。

2·Systemic vascular resistance index (SVRI) and pulmonary vascular resistance index (PVRI) were increased significantly;

外周循环阻力指数、肺循环阻力指数明显增高；

3·Results and Conclusion: Inhaled iloprost can reduce pulmonary vascular resistance and delay the development of primary pulmonary hypertension.

结果和结论：吸入性伊洛前列素治疗可以降低肺血管阻力和延缓原发性肺动脉高压的进程。

4·Whereas mean pulmonary artery pressure (MPAP) and pulmonary vascular resistance (PVR) were significantly higher compared with the control group.

平均肺动脉压（MPAP）、肺血管阻力（PVR）均高于对照组；

5·RESULTS & CONCLUSION: The feature of PAH is that pulmonary vascular resistance progressively increases, and finally leads to right heart failure and death.

结果与结论：肺动脉高压的特点是肺血管阻力进行性增加，最终导致右心衰竭和死亡。

6·Objective To assess the accuracy of Doppler audio-signal processing system(DASPS) in noninvasive automatic estimation of pulmonary vascular resistance (PVR).

目的评价多普勒超声音频处理系统（DASPS）自动定量估测肺血管阻力（PVR ）的准确性。

7·Total pulmonary resistance(TPR), pulmonary vascular resistance(PVR)and systemic vascular resistance(SVR) were increased after injected NOS inhibitor(P<0.05).

在注入NOS抑制剂后总肺循环阻力、肺动脉阻力、体循环血管阻力均明显上升（P< 0 .0 5 ）。

8·Pulmonary artery hypertension (PAH) is a combination of factors caused abnormal pulmonary hemodynamics. Pulmonary vascular resistance (PVR) progressive as clinical features of PAH.

肺动脉高压(PAH)是多种因素引起的肺血流动力学异常，以肺血管阻力进行性升高为临床特征的一组疾病。

9·The manifestations of pulmonary ischemia -reperfusion injury can be characterized by increased pulmonary vascular resistance, decreased oxygenation capacity, worsened compliance, and edema formation.

肺缺血再灌注损伤可以表现为肺血管阻力升高，氧合功能下降，顺应性降低以及水肿形成等等。

10·Pulmonary vascular is an effector of baroreceptor reflex, which can exert significant control of pulmonary resistance and capacitance after orthostatic challenge.

肺血管是压力反射效应器的一部分，立位应激时的压力反射很大程度上控制着肺循环的阻力和容量。